Straits Times Index
3,289.42 -23.93 (-0.72%) S&P 500
5,302.41 +55.73 (+1.06%) Dow
39,851.37 +293.26 (+0.74%) Nasdaq
16,739.84 +228.66 (+1.38%) Bitcoin USD
65,952.42 +4,405.48 (+7.16%) CMC Crypto 200
1,383.97 +116.02 (+9.15%)
Gilead Sciences, Inc. (GILD)
| Previous close | 67.65 |
| Open | 67.94 |
| Bid | 67.21 x 200 |
| Ask | 67.28 x 500 |
| Day's range | 67.23 - 67.98 |
| 52-week range | 64.33 - 87.87 |
| Volume | |
| Avg. volume | 7,146,437 |
| Market cap | 83.758B |
| Beta (5Y monthly) | 0.23 |
| PE ratio (TTM) | 186.75 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.08 (4.55%) |
| Ex-dividend date | 14 Jun 2024 |
| 1y target est | N/A |
- Business Wire
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
SANTA MONICA, Calif., May 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid, Spain.
- Business Wire
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
- Business Wire
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
FOSTER CITY, Calif. & SANTA MONICA, Calif., May 07, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showcase the ongoing commitment to developing differentiated approaches to transform how cancer is treated and span solid tumors and blood cancers, including lung, breast, gastrointestinal, colorectal, leukemia and lymphoma.
